RCS - Redx Pharma Limited - Redx Pharma to present new Phase 2a data at ERS

Jazz PharmaceuticalsAnnouncement

22/09/2025 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250922:nRSV2469Aa&default-theme=true

RNS Number : 2469A  Redx Pharma Limited  22 September 2025

 

 

REDX PHARMA LIMITED

("Redx" or the "Company")

Redx to present new data for zelasudil (RXC007) for the treatment of
Idiopathic Pulmonary Fibrosis at ERS

The oral presentation "Phase 2a signal searching study with zelasudil in
idiopathic pulmonary fibrosis (IPF)" will be presented on Sunday 28 September

Alderley Park, UK,  22 September  2025 Redx Pharma
(https://www.redxpharma.com/) , the clinical-stage biotechnology company
focused on developing novel, small molecule, targeted therapeutics for
fibrotic disease, will present new data from the zelasudil Phase 2a signal
searching study in idiopathic pulmonary fibrosis (IPF) at the European
Respiratory Society (ERS) meeting in Amsterdam. The oral presentation will be
given by Professor Toby Maher, zelasudil Phase 2 Chief Investigator and
Professor of Clinical Medicine and Director of the Interstitial Lung Disease
Programme at Keck School of Medicine at the University of Southern California.

Zelasudil is a potent, oral, small molecule, selective, Rho Associated
Coiled-Coil Containing Protein Kinase 2 (ROCK2) inhibitor. The Phase 2a study
assessed safety, tolerability, pharmacokinetic and initial efficacy in
patients with IPF.

IPF is a debilitating disease of the lungs which progressively causes scarring
and a reduction in lung function. Occurring primarily in older adults (>50
years old), it involves irreversible and variable scarring, stiffening, and
thickening of the lung tissues, leading to patients experiencing shortness of
breath and lack of oxygen absorption. Over 170,000 patients suffer with IPF i 
and around a further 53,000 people are diagnosed each year (US, 5 EU, Japan).
Patients diagnosed with IPF have an estimated life expectancy of 3 to 5
years ii . There is no known cure and current treatment only slows progression
of the disease.

 

 Oral Presentation Details:

 Title: Phase 2a signal searching study with zelasudil in idiopathic pulmonary
 fibrosis (IPF)

 Session: Emerging Clinical Trials in Pulmonary Fibrosis

 Day/Date:  Sunday 28 September 2025

 Presentation Time: 11:05-11:15 CEST

 Location: RAI Amsterdam, Europaboulevard, 1079 MW Amsterdam, Netherlands from
 27 September to 1 October, 2025

 

 For further information, please contact:

 Redx Pharma Limited                              T: +44 (0)1625 469 918

 Cailtin Pearson, Head of Communications

 info@redxpharma.com (mailto:ir@redxpharma.com)

 FTI Consulting                                   T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Limited

Redx Pharma is a clinical-stage biotechnology company focused on the
development of novel, small molecule, targeted medicine for the treatment of
fibrotic disease. Redx aims to progress its programmes to clinical proof of
concept before evaluating options for further development and potential value
creation. The Company is currently progressing an industry-leading ROCK
inhibitor portfolio through the clinic, comprising of zelasudil, a selective
ROCK2 inhibitor for the treatment of interstitial lung diseases including
idiopathic pulmonary fibrosis, and RXC008, a GI-restricted pan-ROCK inhibitor
for the treatment of fibrostenotic Crohn's disease. Additionally, the Company
has a Phase 2 precision oncology programme which it intends to partner for
further development.

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry, translational science and
clinical development, enabling the Company to discover and develop
differentiated therapeutics against biologically or clinically validated
targets. To date, six Redx discovered molecules have been progressed into the
clinic with the Company's accomplishments evidenced not only by its
wholly-owned clinical-stage product candidates and discovery pipeline, but
also by its strategic transactions, which include the sale of pirtobrutinib
(RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor, now
approved by the US FDA, and transactions with both AstraZeneca and Jazz
Pharmaceuticals.

 i  Patient numbers (diagnosed prevalence) & market size forecast data
sourced from Global Data (US, EU5, Japan)

 

 ii  Clinical Estimates from Hyun 2015, Ley 2012, Raghu 2006

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADZGZLRZLGKZG



            Copyright 2019 Regulatory News Service, all rights reserved